Handelsavisen
prelaunch
Companies Healthcare GOHO.TA
GO
GOHO.TA TASE (Tel Aviv) Healthcare Facilities & Services

Goho.Ta

$1 034,00
Open in Charts → Attach watcher ⌖
ILA
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
16,0B ILA
P/E
EV / Rev
Div yield
2,09 %
Op margin
28,6 %
ROE
2,7 %
Net margin
14,9 %
Debt / equity
0,24
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

GOHO.TA operates in the healthcare sector, providing pharmaceutical products and services, primarily generating revenue through the sale of pharmaceuticals and related healthcare services.

Business. GOHO.TA operates in the healthcare sector, providing pharmaceutical products and services, primarily generating revenue through the sale of pharmaceuticals and related healthcare services.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
2,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning GOHO.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to GOHO.TA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    GOHO.TA operates in the healthcare sector, providing pharmaceutical products and services, primarily generating revenue through the sale of pharmaceuticals and related healthcare services.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    GOHO.TA maintains a strong liquidity position, with cash and equivalents amounting to ILS 81.77 million, representing 19.77% of total assets. The company's liquidity FPT (free cash flow to total assets) is negative at -47.05%, indicating a significant outflow of cash relative to asset base. The current ratio of 1.16 suggests the company has sufficient short-term assets to cover its short-term liabilities, though not with a large margin of safety.

    Profitability metrics for GOHO.TA are mixed. The company's return on equity (ROE) is 2.68%, and return on assets (ROA) is 1.78%, both below the typical thresholds for high-performing healthcare firms. The price-to-earnings (P/E) ratio of 2293.22 and price-to-book (P/B) ratio of 61.55 suggest the stock is highly valued relative to earnings and book value, which may reflect investor expectations of future growth or market sentiment.

    The company's revenue is concentrated in the pharmaceuticals segment, with no disclosed geographic diversification in the provided data. This concentration may expose the company to specific market risks, such as regulatory changes or shifts in demand for pharmaceutical products.

    Looking ahead, GOHO.TA's growth trajectory is uncertain. The company's free cash flow is negative at ILS -192.20 million, and capital expenditures are ILS -5.25 million, indicating ongoing investment in operations. However, the lack of disclosed revenue growth rates or segment-specific growth projections makes it difficult to assess the company's future performance.

    Risk factors for GOHO.TA include liquidity and dilution risks, both of which are currently rated as low. The company has no immediate filing-based liquidity or dilution flags, and the dilution potential is minimal given the equal number of basic and diluted shares outstanding.

    Recent events and filings for GOHO.TA do not indicate any significant changes in the company's operations or financial position. The absence of recent earnings calls or regulatory filings suggests a stable but uneventful period for the company.

    Key takeaways
    • GOHO.TA has a strong liquidity position with significant cash reserves but a negative free cash flow to total assets ratio.
    • The company's profitability metrics are below industry norms, and its stock is highly valued relative to earnings and book value.
    • Revenue is concentrated in the pharmaceuticals segment, with no disclosed geographic diversification.
    • Growth trajectory is uncertain due to negative free cash flow and lack of detailed growth projections.
    • Liquidity and dilution risks are currently low, with no immediate filing-based flags.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1 034,00
    Market cap
    $16.66B
    Enterprise value
    $16.65B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    1588.6x
    P / B
    61.5x
    P / Tangible book
    61.5x
    Tangible book
    $270.8M
    Net cash
    $18.1M
    Current ratio
    1.2
    Debt / equity
    0.2
    ROA
    1.8%
    ROE
    2.7%
    Cash conversion
    144.0%
    CapEx / revenue
    -10.8%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin28,6 %Best in class
    Net Margin14,9 %Above P75
    ROE2,7 %Below median
    Capex / Rev-10,8 %Below median
    D/E0,24Above median
    Cash Conv1,44Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • GOHO.TA Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    GOHO.TACanonical
    TASE (Tel Aviv) · ILA

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage